PRELUDE THERAPEUTICS INC Temporary Equity, Carrying Amount, Attributable to Parent
PRELUDE THERAPEUTICS INC (PRLD) had Temporary Equity, Carrying Amount, Attributable to Parent of $66.44 million as of 2019-12-31, per its 10-K filed 2021-03-16.
Discontinued › Balance Sheet › Equity › Temporary Equity
us-gaap:TemporaryEquityCarryingAmountAttributableToParent · last filed 2021-03-16
- 2019-12-31: Temporary Equity, Carrying Amount, Attributable to Parent $66.44M.
| Period end | Temporary Equity, Carrying Amount, Attributable to Parent |
|---|---|
| 2019-12-31 | $66.44M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |